<DOC>
	<DOCNO>NCT00169988</DOCNO>
	<brief_summary>The Recognition Prevention ( RAP ) Program conduct research study compare antidepressant , sertraline , alone versus combination second-generation antipsychotic , risperidone , evaluate ability reduce unusual thought , suspiciousness unusual experience , improve reason ability , memory , attention social skill adolescent .</brief_summary>
	<brief_title>Antidepressant Antipsychotic Treat Attenuated Positive Negative Symptoms</brief_title>
	<detailed_description>Eligible patient enrol 16-week trial consist symptom side effect rating ( 10 visit ) , monthly blood urine test , neuropsychological test first last visit . At initial appointment , patient assign sertraline randomly assign adjunctive risperidone placebo group . The treat physician also blind medication assignment , allow doctor patient assess side effect symptom improvement , unbiased expectation . All patient receive active medication .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Schizotypal Personality Disorder</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Participants age 12 22 . Participants Englishspeaking . Participants experience one symptom like unusual thought , suspiciousness , unusual perceptual experience . Participants meet additional RAP criterion ( evaluate screen interview ) . Participants diagnose Axis I psychotic disorder , include : schizophreniform disorder , schizophrenia , schizoaffective disorder , bipolar disorder , major depression psychotic feature . Participants history neurological , neuroendocrine , medical condition know affect brain . Participants medical condition contraindicates treatment sertraline risperidone . Participants past current substance dependence . Participants currently take respond well antidepressant antipsychotic medication</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>22 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>clinical high risk</keyword>
	<keyword>attenuate positive symptom</keyword>
	<keyword>attenuate negative symptom</keyword>
	<keyword>cognition</keyword>
	<keyword>functional status</keyword>
	<keyword>prodromal psychosis</keyword>
</DOC>